文献速递类风湿关节炎

难治性类风湿关节炎全球患病率:系统综述与荟萃分析

Difficult-to-treat rheumatoid arthritis: systematic review and meta-analysis on global prevalence.
PubMed 文献 · Ann Rheum Dis · 2025-11-03

D2T-RA汇总患病率为11.7%(95%CI 9.5%-14.3%),约47.1%的D2T-RA患者存在持续性炎症难治性RA证据。更严格定义下患病率明显下降:≥3种b/tsDMARD失败者为4.3%,≥4种失败者为1.6%。

要点

  • 全球D2T-RA汇总患病率为11.7%(95%CI 9.5%-14.3%)。
  • 约47.1%的D2T-RA患者有持续性炎症难治性RA证据。
  • ≥3种b/tsDMARD失败者患病率4.3%,≥4种失败者1.6%。

核心结论

  • 基于现有全球数据,约12%的RA患者符合标准D2T-RA定义,近半数表现为持续性炎症疾病。
  • 采用≥3种b/tsDMARD失败的更严格定义可识别需要创新治疗或策略的小部分患者。

研究设计与样本

  • 系统检索PubMed、EMBASE和Cochrane Library(截至2025年4月)中按EULAR定义报告D2T-RA患病率的观察性研究。

主要发现

  • D2T-RA全球汇总患病率为11.7%(95%CI 9.5%-14.3%)。
  • 总体RA队列中D2T-RA汇总患病率为10.9%(95%CI 8.2%-14.2%),限于b/tsDMARDs治疗人群的研究中为13.2%(95%CI 9.1%-18.8%)。
  • 约半数D2T-RA患者存在持续性炎症难治性RA证据(汇总比例47.1%,95%CI 33.3%-61.4%)。
  • 更严格定义下患病率急剧下降:D2T(3)-RA(≥3种b/tsDMARD失败)为4.3%(2.7%-6.7%),D2T(4)-RA(≥4种失败)为1.6%(0.6%-4.3%)。

关键数值与推荐

  • D2T-RA按EULAR定义判定,全球汇总患病率11.7%(95%CI 9.5%-14.3%)。
  • 持续性炎症难治性RA在D2T-RA中的汇总比例为47.1%(95%CI 33.3%-61.4%)。
  • D2T(3)-RA(≥3种b/tsDMARD失败)患病率4.3%(95%CI 2.7%-6.7%),D2T(4)-RA(≥4种失败)患病率1.6%(95%CI 0.6%-4.3%)。

临床怎么用

  • 按EULAR定义评估时,约12%的RA患者符合D2T-RA标准,其中近半数有持续性炎症证据。
  • 采用≥3种b/tsDMARD失败的更严格定义可识别需要创新治疗或策略的小部分患者。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Despite significant advances in targeted therapies, difficult-to-treat rheumatoid arthritis (D2T-RA) remains a major clinical challenge. This study aimed to systematically evaluate the global prevalence of D2T-RA using the European League Against Rheumatism (EULAR) definition and to quantify the proportion attributable to persistent inflammatory refractory rheumatoid arthritis (RA). METHODS: We comprehensively searched PubMed, EMBASE, and Cochrane Library (up to April 2025) for observational studies reporting the prevalence of D2T-RA according to the EULAR definition. Subgroup analyses were performed to explore heterogeneity sources. Random-effects meta-analysis of proportions using generalised linear mixed models was conducted to calculate pooled prevalence rates and 95% CI. RESULTS: Twenty-three studies with 27,987 patients with RA from 13 countries were included. The global pooled prevalence of D2T-RA was 11.7% (95% CI: 9.5%-14.3%). The pooled prevalence of D2T-RA was 10.9% (95% CI: 8.2%-14.2%) in overall RA cohorts and 13.2% (95% CI: 9.1%-18.8%) in studies restricted to biologic and target synthetic disease-modifying antirheumatic drugs (b/tsDMARDs)-treated populations. D2T-RA prevalence was stable in the region, RA criteria, and study setting; significant variations only existed in the enrolled period (pre-2020 vs post-2020: 9.86% [95% CI: 7.6%-12.7%] vs 14.3% [95% CI: 10.3%-19.6%]; P = .08). Moreover, about half of patients with D2T-RA exhibited evidence of persistent inflammatory refractory RA (pooled proportion: 47.1%, 95% CI: 33.3%-61.4%). Prevalence decreased sharply with stricter definitions: D2T(3)-RA (≥3 b/tsDMARD failures): 4.3% (2.7%-6.7%) and D2T(4)-RA (≥4 failures: 1.6% (0.6%-4.3%). CONCLUSIONS: Based on available global data, approximately 12% of patients with RA meet standard D2T-RA criteria, with nearly half exhibiting persistent inflammatory disease. Stricter definitions with failure of ≥3 b/tsDMARD identify the small group of patients for whom innovative treatments or strategies are needed.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Xie W, Chen T, Xiao S, et al. Difficult-to-treat rheumatoid arthritis: systematic review and meta-analysis on global prevalence. Ann Rheum Dis. 2025. PMID: 41188120. doi:10.1016/j.ard.2025.10.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。